165 related articles for article (PubMed ID: 38233795)
1. UTP11 promotes the growth of hepatocellular carcinoma by enhancing the mRNA stability of Oct4.
Chen Y; Zhang X; Zhang M; Fan W; Lin Y; Li G
BMC Cancer; 2024 Jan; 24(1):93. PubMed ID: 38233795
[TBL] [Abstract][Full Text] [Related]
2. YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation.
Zhang C; Huang S; Zhuang H; Ruan S; Zhou Z; Huang K; Ji F; Ma Z; Hou B; He X
Oncogene; 2020 Jun; 39(23):4507-4518. PubMed ID: 32366907
[TBL] [Abstract][Full Text] [Related]
3. Blood exosome marker miRNA-30d-5p: Role and regulation mechanism in cell stemness and gemcitabine resistance of hepatocellular carcinoma.
Tang B; Xie L; Tang X; Tian J; Xiao S
Mol Cell Probes; 2023 Oct; 71():101924. PubMed ID: 37536457
[TBL] [Abstract][Full Text] [Related]
4. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma.
Huang S; Sun L; Hou P; Liu K; Wu J
Front Immunol; 2022; 13():944898. PubMed ID: 36148220
[TBL] [Abstract][Full Text] [Related]
5. Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway.
Li B; Cao Y; Meng G; Qian L; Xu T; Yan C; Luo O; Wang S; Wei J; Ding Y; Yu D
EBioMedicine; 2019 Jan; 39():239-254. PubMed ID: 30555042
[TBL] [Abstract][Full Text] [Related]
6. Long non-coding RNA LINC01503 promotes the progression of hepatocellular carcinoma via activating MAPK/ERK pathway.
Wang MR; Fang D; Di MP; Guan JL; Wang G; Liu L; Sheng JQ; Tian DA; Li PY
Int J Med Sci; 2020; 17(9):1224-1234. PubMed ID: 32547318
[No Abstract] [Full Text] [Related]
7. [High expression of UBE2S promotes progression of hepatocellular carcinoma by increasing cancer cell stemness].
Chen H; Li Z; Wang M; Lu L; Tang Q; Luo L
Nan Fang Yi Ke Da Xue Xue Bao; 2024 Mar; 44(3):455-464. PubMed ID: 38597436
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-Dependent Kinase 4 is expected to be a therapeutic target for hepatocellular carcinoma metastasis using integrated bioinformatic analysis.
Zhang JN; Wei F; Lei LH; Yang Y; Yang Y; Zhou WP
Bioengineered; 2021 Dec; 12(2):11728-11739. PubMed ID: 34784846
[TBL] [Abstract][Full Text] [Related]
9. Activation of IL6/IGFIR confers poor prognosis of HBV-related hepatocellular carcinoma through induction of OCT4/NANOG expression.
Chang TS; Wu YC; Chi CC; Su WC; Chang PJ; Lee KF; Tung TH; Wang J; Liu JJ; Tung SY; Kuo LM; Ho HN; Ling TY; Huang YH
Clin Cancer Res; 2015 Jan; 21(1):201-10. PubMed ID: 25564572
[TBL] [Abstract][Full Text] [Related]
10. Metadherin promotes stem cell phenotypes and correlated with immune infiltration in hepatocellular carcinoma.
Wang YY; Shen MM; Gao J
World J Gastroenterol; 2024 Feb; 30(8):901-918. PubMed ID: 38516242
[TBL] [Abstract][Full Text] [Related]
11. LINC00680 enhances hepatocellular carcinoma stemness behavior and chemoresistance by sponging miR-568 to upregulate AKT3.
Shu G; Su H; Wang Z; Lai S; Wang Y; Liu X; Dai L; Bi Y; Chen W; Huang W; Zhou Z; He S; Dai H; Tang B
J Exp Clin Cancer Res; 2021 Jan; 40(1):45. PubMed ID: 33499874
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of EWSR1 (Ewing sarcoma breakpoint region 1/EWS RNA binding protein 1) predicts poor survival in patients with hepatocellular carcinoma.
Jiang W; Wu T; Shi X; Xu J
Bioengineered; 2021 Dec; 12(1):7941-7949. PubMed ID: 34612781
[TBL] [Abstract][Full Text] [Related]
13. Novel tumor suppressor SPRYD4 inhibits tumor progression in hepatocellular carcinoma by inducing apoptotic cell death.
Zahid KR; Han S; Zhou F; Raza U
Cell Oncol (Dordr); 2019 Feb; 42(1):55-66. PubMed ID: 30238408
[TBL] [Abstract][Full Text] [Related]
14. The lncRNA
Zhou N; Li S; Wu D; Zhang F; Tang F; Li Y
DNA Cell Biol; 2021 Oct; 40(10):1278-1289. PubMed ID: 34558987
[TBL] [Abstract][Full Text] [Related]
15. Over-activation of EFTUD2 correlates with tumor propagation and poor survival outcomes in hepatocellular carcinoma.
Lv C; Li XJ; Hao LX; Zhang S; Song Z; Ji XD; Gong B
Clin Transl Oncol; 2022 Jan; 24(1):93-103. PubMed ID: 34282556
[TBL] [Abstract][Full Text] [Related]
16. Fanconi Anemia Complementation Group E, a DNA Repair-Related Gene, Is a Potential Marker of Poor Prognosis in Hepatocellular Carcinoma.
Takahashi J; Masuda T; Kitagawa A; Tobo T; Nakano Y; Abe T; Ando Y; Kosai K; Kobayashi Y; Matsumoto Y; Yoshizumi T; Mori M; Mimori K
Oncology; 2022; 100(2):101-113. PubMed ID: 34724663
[TBL] [Abstract][Full Text] [Related]
17. Centromere protein N may be a novel malignant prognostic biomarker for hepatocellular carcinoma.
Wang Q; Yu X; Zheng Z; Chen F; Yang N; Zhou Y
PeerJ; 2021; 9():e11342. PubMed ID: 33987018
[TBL] [Abstract][Full Text] [Related]
18. Overexpressed GNAZ predicts poor outcome and promotes G0/G1 cell cycle progression in hepatocellular carcinoma.
Tian F; Cai D
Gene; 2022 Jan; 807():145964. PubMed ID: 34530087
[TBL] [Abstract][Full Text] [Related]
19. Mining featured biomarkers associated with vascular invasion in HCC by bioinformatics analysis with TCGA RNA sequencing data.
Zhang R; Ye J; Huang H; Du X
Biomed Pharmacother; 2019 Oct; 118():109274. PubMed ID: 31545220
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-induced lncRNA MRVI1-AS1 accelerates hepatocellular carcinoma progression by recruiting RNA-binding protein CELF2 to stabilize SKA1 mRNA.
Tuo H; Liu R; Wang Y; Yang W; Liu Q
World J Surg Oncol; 2023 Mar; 21(1):111. PubMed ID: 36973749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
